Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARγ

被引:81
作者
Ge, Heng
Zhang, Jun-feng
Guo, Bing-shi
He, Qing
Wang, Bin-yao
He, Ben
Wang, Chang-qian
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Cardiol, Shanghai 200092, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 3, Dept Cardiol, Shanghai 200092, Peoples R China
[3] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200031, Peoples R China
关键词
EMMPRIN; PPAR gamma; MMPs; resveratrol; macrophages;
D O I
10.1016/j.vph.2006.08.412
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The effect of resveratrol on macrophage EMMPRIN expression and its potential mechanism was investigated. Both EMMPRIN expression and MMP-9 activity, respectively assayed by Western blot and zymography, were greatly up-regulated during PMA-induced macrophage differentiation from THP-1 monocytes. Both resveratrol and a PPAR gamma agonist, pioglitazone, significantly inhibited EMMPRIN expression and MMP-9 activity in a concentration-dependent manner. The effects of pioglitazone and resveratrol were reversed by pretreatment of THP-1 cells with a PPAR gamma antagonist, GW9662, prior to PMA induction. Thus, data suggest that resveratrol may down-regulate EMMPRIN and MMP-9 through PPAR gamma activation. This possibility was further examined in resveratrol-or pioglitazone-treated U937 cells, which had been co-transfected with a PPAR gamma expression vector and a luciferase reporter vector containing three tandem repeats of PPRE in cis. Results of the agonist-activated luciferase assay showed that resveratrol activated PPAR gamma in a concentration-dependent manner. Since EMMPRIN and MMP-9 up-regulation is associated with activation of the NF-kappa B pathway, we investigated the effect of pioglitazone and resveratrol on TNF-alpha-induced NF-kappa B activation. Western blot results indicated that both pioglitazone and resveratrol markedly inhibited the NF-kappa B pathway through suppressing I kappa B protein phosphorylation in macrophages, although this effect of resveratrol was not reversed by GW9662. In conclusion, resveratrol can down-regulate EMMPRIN expression by macrophages via activating PPAR gamma. This may be a primary mechanism of its inhibitory effect on MMP-9. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:114 / 121
页数:8
相关论文
共 41 条
[1]
Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins [J].
Belguendouz, L ;
Fremont, L ;
Linard, A .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (09) :1347-1355
[2]
Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.0.CO
[3]
2-#
[4]
Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial [J].
Brown, DL ;
Desai, KK ;
Vakili, BA ;
Nouneh, C ;
Lee, HM ;
Golub, LM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (04) :733-738
[5]
Role of nuclear factor-κB activation in metalloproteinase-1,-3, and-9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo [J].
Chase, AJ ;
Bond, M ;
Crook, MF ;
Newby, AC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (05) :765-771
[6]
Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells [J].
Di Santo, A ;
Mezzetti, A ;
Napoleone, E ;
Di Tommaso, R ;
Donati, MB ;
De Gaetano, G ;
Lorenzet, R .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) :1089-1095
[7]
Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells - A potential protective mechanism in plaque stability [J].
Fabunmi, RP ;
Sukhova, GK ;
Sugiyama, S ;
Libby, P .
CIRCULATION RESEARCH, 1998, 83 (03) :270-278
[8]
GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501
[9]
Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK [J].
Hagemann, T ;
Wilson, J ;
Kulbe, H ;
Li, NFF ;
Leinster, DA ;
Charles, K ;
Klemm, F ;
Pukrop, T ;
Binder, C ;
Balkwill, FR .
JOURNAL OF IMMUNOLOGY, 2005, 175 (02) :1197-1205
[10]
Matrix metalloproteinases and coronary artery diseases [J].
Ikeda, U ;
Shimada, K .
CLINICAL CARDIOLOGY, 2003, 26 (02) :55-59